[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Gray et al., 1999 - Google Patents

The K‐Opioid Agonist, U‐69593, Decreases Acute Amphetamine‐Evoked Behaviors and Calcium‐Dependent Dialysate Levels of Dopamine and Glutamate in the …

Gray et al., 1999

Document ID
13498342497168297030
Author
Gray A
Rawls S
Shippenberg T
McGinty J
Publication year
Publication venue
Journal of neurochemistry

External Links

Snippet

The effect of ak‐opioid receptor agonist on acute amphetamine‐induced behavioral activation and dialysate levels of dopamine and glutamate in the ventral striatum were investigated. Amphetamine (2.5 mg/kg ip) evoked a substantial increase in rearing, sniffing …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epihephrine, salbutamol, ephedrine or methadone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids

Similar Documents

Publication Publication Date Title
Gray et al. The K‐Opioid Agonist, U‐69593, Decreases Acute Amphetamine‐Evoked Behaviors and Calcium‐Dependent Dialysate Levels of Dopamine and Glutamate in the Ventral Striatum
Auclair et al. D-Amphetamine fails to increase extracellular dopamine levels in mice lacking α1b-adrenergic receptors: relationship between functional and nonfunctional dopamine release
Matthes et al. Activity of the δ-opioid receptor is partially reduced, whereas activity of the κ-receptor is maintained in mice lacking the μ-receptor
Glick et al. 18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats
Ingram et al. Enhanced opioid efficacy in opioid dependence is caused by an altered signal transduction pathway
Alkondon et al. Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks
Marona-Lewicka et al. Reinforcing effects of certain serotonin-releasing amphetamine derivatives
Davis et al. d-Methadone blocks morphine tolerance andN-methyl-D-aspartate-induced hyperalgesia
Ceglia et al. Effects of chronic treatment with escitalopram or citalopram on extracellular 5‐HT in the prefrontal cortex of rats: role of 5‐HT1A receptors
Huang et al. Nicotine reduces L-DOPA-induced dyskinesias by acting at β2* nicotinic receptors
Connor et al. Modulation of Ca2+ channel currents of acutely dissociated rat periaqueductal grey neurons
Camarero et al. Studies, using in vivo microdialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3, 4‐methylenedioxymethamphetamine (‘ecstasy’)‐induced dopamine release and free radical formation in the mouse striatum
Bie et al. cAMP-mediated mechanisms for pain sensitization during opioid withdrawal
Rasmussen et al. The novel 5-hydroxytryptamine1A antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine
Lanteri et al. Drugs of abuse specifically sensitize noradrenergic and serotonergic neurons via a non-dopaminergic mechanism
Peñalva et al. Effect of sleep and sleep deprivation on serotonergic neurotransmission in the hippocampus: a combined in vivo microdialysis/EEG study in rats
Corongiu et al. Adolescence versus adulthood: Differences in basal mesolimbic and nigrostriatal dopamine transmission and response to drugs of abuse
Wolf et al. Amphetamine increases glutamate efflux in the rat ventral tegmental area by a mechanism involving glutamate transporters and reactive oxygen species
Torrecilla et al. Pre‐and postsynaptic regulation of locus coeruleus neurons after chronic morphine treatment: a study of GIRK‐knockout mice
Banks et al. Antisecretory actions of a novel vasoactive intestinal polypeptide (VIP) antagonist in human and rat small intestine
Kemppainen et al. Opioidergic modulation of ethanol self‐administration in the ventral pallidum
Schaefer et al. Short‐and long‐term effects of (+)‐methamphetamine and (±)‐3, 4‐methylenedioxymethamphetamine on monoamine and corticosterone levels in the neonatal rat following multiple days of treatment
Bianchi et al. Supraspinal Gβγ‐dependent stimulation of PLCβ3 originating from G inhibitory protein‐μ opioid receptor‐coupling is necessary for morphine induced acute hyperalgesia
Rossi et al. Serotonin‐1A receptor function in the dorsal raphe nucleus following chronic administration of the selective serotonin reuptake inhibitor sertraline
Shinohara et al. Noradrenaline enhances the excitatory effects of dopamine on medial prefrontal cortex pyramidal neurons in rats